Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
Clinical trial NCT07457528 · RECRUITING
Trial details
- NCT number
- NCT07457528
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-12
- Primary completion
- 2027-06-30
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.